PeppiLibrary

Growth Hormone

CJC-1295 peptide reference

GHRH analog. Two variants — with or without DAC — have very different cadences.

Last reviewed May 6, 2026 Human data Not FDA approved
Peppi reviewing CJC-1295 notes
Default dose label100 mcg
Preferred routeSubQ
Frequency labelNo DAC: 1–3× daily. With DAC: 1× weekly.
Storage window30 days mixed

Evidence snapshot

Human data

Evidence maturityHuman data
Limited human studies (clinical trials by ConjuChem terminated)

Research chemical (US)

Route map

How records are usually labeled

1 SubQ
2 IM

Rotate within the abdomen.

Vial timeline

Storage cues to log

Before mixRefrigerate 2–8 °C; freeze long-term.
After mixRefrigerate 2–8 °C, use within 30 days.
Use-by cue30 days after mixing
Mixed vial window30 days
Use this as a record-keeping cue, not a replacement for product labeling.

Peppi workflow

From vial to review

Vial 2 mg vial
Dose 100 mcg
Route SubQ
Review 30d storage

Peppi turns scattered dose, vial, route, storage, note, and report details into one record trail.

Educational reference only

This page helps you understand what to track for CJC-1295. It is not medical advice, a prescription, or a recommendation to use this peptide. Discuss dose, route, timing, storage, and safety with a qualified healthcare professional.

Overview

CJC-1295 is a modified GHRH(1-29) analog. The 'no DAC' variant (Mod GRF 1-29) has a short half-life and is dosed multiple times daily. The 'with DAC' variant covalently binds to serum albumin via a Drug Affinity Complex, extending its half-life to days and allowing weekly dosing. Typically stacked with a ghrelin agonist like Ipamorelin.

Also known as: Mod GRF 1-29 (no DAC), DAC:GRF (with DAC).

Sustained GH elevationCombined with secretagogue for amplified pulseRecovery and body composition

Mechanism and timing snapshot

GHRH-receptor agonist with stabilising substitutions resisting enzymatic degradation. The DAC variant adds a maleimidopropionic acid linker that binds plasma albumin.

Onset label15 min
Catalog onset field, when available.
Half-life label168 hr
No DAC: ~30 min. With DAC: ~6–8 days due to albumin binding.
Duration label168 hr
Catalog duration field, when available.
subQ High
IM High
oral Negligible

Tracking defaults

These values come from Peppi's catalog so records can be prefilled consistently. They should be reviewed against your clinician's instructions before logging real-world use.

Catalog default dose100 mcg
Catalog dose range100 mcg - 2 mg
Default routeSubQ
Frequency labelNo DAC: 1–3× daily. With DAC: 1× weekly.
Best time labelNo DAC: pre-bed and/or post-workout, empty stomach. With DAC: any consistent day of the week.
Food noteEmpty stomach for the no-DAC variant; less critical for DAC due to sustained levels.

Catalog protocol note

No DAC: 100 mcg subQ 1–3× daily. With DAC: 1–2 mg subQ once weekly.

Routes and site notes

Available route labelsSubQ, IM
Preferred route labelSubQ
Common site labelsAbdomen
Site rotation noteRotate within the abdomen.

Chemistry

SequenceYADAIFTNSYRKVLGQLSARKLLQDIMSR (modified)
Amino acids29
Molecular formulaC152H252N44O42 (no DAC)
Molecular weight3367 Da

Vial, reconstitution, and storage

Supply formLyophilized powder
Typical vial size2 mg
DiluentBacteriostatic water
Diluent volume2 mL
Concentration note2 mg in 2 mL → 0.10 mL = 100 mcg (10 units on a 100-unit insulin syringe).
Before reconstitutionRefrigerate 2–8 °C; freeze long-term.
After reconstitutionRefrigerate 2–8 °C, use within 30 days.
Reconstituted shelf life30 days
Light sensitiveYes
Freeze/thaw warningYes

Safety notes

Common and rare side effects listed in the catalog

  • Injection-site flushing
  • Headache
  • Mild fluid retention
  • Numbness/tingling
  • Joint stiffness

Contraindications and warnings

  • Active malignancy
  • Severe cardiac disease
  • Confirm DAC vs no-DAC variant — protocols differ significantly.

Other considerations

  • Always verify the variant on your vial before dosing.
  • DAC version produces a sustained 'bleed' of GH rather than discrete pulses.

Evidence and regulatory context

Evidence levelLimited human studies (clinical trials by ConjuChem terminated)
FDA approvedNo
Regulatory statusResearch chemical (US)
Prescription requiredNo
Approved countriesNot listed

Stacking and cycle notes

Stacks well withipamorelin
Avoid combining noteOther GHRH analogs simultaneously
Typical cycle label8–16
Typical break label4–8
Cycle guidanceLong cycles are typical; some users run continuously with periodic breaks.

Tracking tips

  • Read the label carefully — DAC and no-DAC look identical but dose 50× apart per dosing event.
  • No-DAC pairs with Ipamorelin for an amplified pulse.
  • DAC gives smoother levels but blunts pulsatility — may suit anti-aging more than performance.

References

Track it in Peppi

Keep CJC-1295 records organized.

Use Peppi for dose logs, vial inventory, storage dates, reminders, journal notes, photos, and clinician-ready reports.

Download on theApp Store Get it onGoogle Play

FAQ

What should I track for CJC-1295?

Track the peptide name, dose amount and unit, route, vial label, timing, reconstitution or expiration dates, storage notes, and any symptoms or questions for clinician review.

Does Peppi tell me how to use CJC-1295?

No. Peppi organizes educational reference and your own records. Protocol decisions should come from a qualified healthcare professional.

Can I export CJC-1295 records?

Peppi is designed to keep dose logs, vial inventory, journal notes, and reports easier to review and export.

Last reviewed: May 6, 2026